

iOmx Therapeutics submits Clinical Trial Application for IOMX-0675

- *IOMX-0675 selectively targets LILRB1 and LILRB2, key immunosuppressive receptors, while sparing immune-activating family members*
- *IOMX-0675 reprograms myeloid cells and restores cytotoxic T cell function, demonstrating strong anti-tumor potential*

Martinsried / Munich, Germany, December 19, 2024 - iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs, today announced the submission of the Clinical Trial Application (CTA) for IOMX-0675, the second pipeline candidate. IOMX-0675 is a proprietary, dual-targeting, fully human antibody designed to address the key immune-regulatory LILR receptor family expressed on myeloid and lymphoid immune cells.

Specifically, IOMX-0675 targets LILRB1 and LILRB2, the two most potent immunosuppressive receptors within this family, while sparing closely related immune-activating receptors LILRA1 and LILRA3. By selectively neutralizing these immunosuppressive receptors, IOMX-0675 reprograms the immunosuppressive myeloid compartment and restores cytotoxic T cell activity, as demonstrated in preclinical studies, unleashing the full anti-tumor potential of the immune system.

“The submission of the CTA for IOMX-0675 marks another key milestone on our journey to translate novel immune evasion biology into a pipeline of clinical-stage projects,” said **Apollon Papadimitriou, Ph.D., Chief Executive Officer of iOmx**. “With its unique and highly differentiated profile, IOMX-0675 stands out as a best-in-class antibody in a target class that is increasingly supported by clinical validation. I am convinced that IOMX-0675 has the potential to become a transformative treatment for cancer patients in need.”

About iOmx Therapeutics

iOmx Therapeutics (www.iomx.com) is a clinical-stage company that harnesses deep tumor and myeloid biology insights to generate novel treatments for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity, iOmx is creating potential new backbone therapies in a modality-open fashion. By applying its comprehensive drug discovery & development expertise iOmx is committed to shaping the future of cancer therapy. The company's **lead program, OMX-0407, is a proprietary first-in-class spectrum-selective kinase inhibitor** targeting key oncology-relevant tyrosine kinases and salt-inducible kinases (SIKs) and is currently being investigated in a Phase Ia/Ib clinical trial in multiple solid tumors. The second program, **IOMX-0675, a highly differentiated, LILRB1&2 cross-specific antibody** is preparing to advance into clinical development following CTA submission in Q4 2024. iOmx is backed by international venture capital investors, such as Athos, Sofinnova Partners,



Wellington Partners, MIG Capital and M Ventures. The Company is based in Martinsried/Munich, Germany.

Media contact

MC Services AG

Katja Arnold, Julia von Hummel, Shaun Brown

T: +49(0)89 2102280

iomx@mc-services.eu